View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
 PRESS RELEASE

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient F...

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company’s progress in addressing therapeutic gaps in immuno-inflammator...

MongoDB Inc: 1 director

A director at MongoDB Inc sold 31,000 shares at 320.277USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

Friedman Industries, Incorporated Announces Cash Dividend

Friedman Industries, Incorporated Announces Cash Dividend LONGVIEW, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of Friedman Industries, Incorporated, (NASDAQ/GS: FRD) a Texas-based company engaged in metals processing, pipe manufacturing, and metals distribution, declared on September 18, 2025, a cash dividend of $0.04 per share on the Common Stock of the Company. The Company will pay the cash dividend on November 14, 2025 to shareholders of record at the close of business on October 24, 2025. This dividend marks the Company’s 215th consecutive quarterly...

Anish Jog ... (+6)
  • Anish Jog
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig

Takeaways from 2025 MondoDB Investor Day; Incrementally Bullish on Str...

Voyage AI Still in the Early Innings of Integration; Embedding Models Still in Early Innings. The company’s recent acquisition of Voyage AI remains a critical part of MDB’s AI strategy for building reliable AI apps and reliable models by connecting private and proprietary customer data directly to

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
 PRESS RELEASE

Dave & Buster’s Reports Second Quarter 2025 Financial Results

Dave & Buster’s Reports Second Quarter 2025 Financial Results DALLAS, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), (“Dave & Buster's” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its second quarter of fiscal 2025 ended August 5, 2025. Second Quarter 2025 Financial Summary Second quarter revenue was $557.4 million, a .05% increase compared to the second quarter of fiscal 2024.Comparable store sales decreased 3.0% compared to the same calendar period in fiscal 2024...

Anish Jog ... (+6)
  • Anish Jog
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Present...

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of AT...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch